Wells Fargo & Company Forecasts Strong Price Appreciation for Cigna Group (NYSE:CI) Stock

Key Points

• Wells Fargo raised its price target on Cigna to $305 while maintaining an "equal weight" rating—implying about a 6.9% upside—and Wall Street consensus remains a Moderate Buy with an average target near $333.11.
• Cigna beat Q1 estimates with EPS $7.79 (vs. $7.60) and revenue $68.52B (vs. $66.29B) and raised FY2026 adjusted EPS guidance to at least $30.35; the stock trades around $285 with a P/E of 12.87 and a $75.2B market cap.
• Key near-term risks include Cigna’s planned exit from the ACA individual market (~369,000 members) and persistent pharmacy/PBM cost volatility that could pressure margins; insiders have sold modestly while institutional ownership remains high (~87%).

Cigna Group (NYSE:CI - Get Free Report) had its target price hoisted by equities researchers at Wells Fargo & Company from $300.00 to $305.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an "equal weight" rating on the health services provider's stock. Wells Fargo & Company's price objective would suggest a potential upside of 6.86% from the stock's current price.

Other analysts have also issued reports about the company. UBS Group reiterated a "buy" rating and issued a $375.00 price objective on shares of Cigna Group in a research report on Monday, February 9th. Piper Sandler lowered their price objective on Cigna Group from $374.00 to $370.00 and set an "overweight" rating for the company in a research report on Tuesday, March 3rd. TD Cowen lifted their price objective on Cigna Group from $333.00 to $338.00 and gave the stock a "buy" rating in a research report on Monday, February 9th. Barclays reiterated an "overweight" rating and issued a $310.00 price objective on shares of Cigna Group in a research report on Friday. Finally, Leerink Partners lifted their price objective on Cigna Group from $270.00 to $297.00 and gave the stock a "market perform" rating in a research report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Cigna Group currently has a consensus rating of "Moderate Buy" and an average target price of $333.11.

Cigna Group Price Performance

Shares of Cigna Group stock traded down $5.16 during trading on Friday, reaching $285.42. The company's stock had a trading volume of 156,421 shares, compared to its average volume of 1,678,751. The stock has a 50-day moving average price of $274.34 and a two-hundred day moving average price of $276.94. The company has a current ratio of 0.74, a quick ratio of 0.74 and a debt-to-equity ratio of 0.74. Cigna Group has a one year low of $239.51 and a one year high of $350.00. The stock has a market capitalization of $75.22 billion, a P/E ratio of 12.87, a price-to-earnings-growth ratio of 1.01 and a beta of 0.26.

Cigna Group (NYSE:CI - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The health services provider reported $7.79 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $7.60 by $0.19. Cigna Group had a return on equity of 19.46% and a net margin of 2.17%.The business had revenue of $68.52 billion during the quarter, compared to analysts' expectations of $66.29 billion. During the same period in the previous year, the business posted $6.74 earnings per share. The firm's revenue for the quarter was up 4.6% compared to the same quarter last year. Cigna Group has set its FY 2026 guidance at 30.350- EPS. As a group, sell-side analysts anticipate that Cigna Group will post 30.32 EPS for the current fiscal year.

Insider Activity

In other news, insider Nicole S. Jones sold 2,307 shares of Cigna Group stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $288.91, for a total transaction of $666,515.37. Following the transaction, the insider directly owned 32,647 shares of the company's stock, valued at $9,432,044.77. This trade represents a 6.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Everett Neville sold 1,719 shares of Cigna Group stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $288.91, for a total transaction of $496,636.29. Following the transaction, the insider directly owned 5,670 shares in the company, valued at approximately $1,638,119.70. This represents a 23.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.60% of the stock is currently owned by insiders.

Institutional Trading of Cigna Group

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Cigna Group by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 26,173,577 shares of the health services provider's stock valued at $7,203,754,000 after purchasing an additional 414,834 shares during the period. State Street Corp grew its position in shares of Cigna Group by 1.8% in the 4th quarter. State Street Corp now owns 12,339,250 shares of the health services provider's stock valued at $3,396,132,000 after purchasing an additional 224,122 shares during the period. Massachusetts Financial Services Co. MA grew its position in shares of Cigna Group by 8.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 11,805,083 shares of the health services provider's stock valued at $3,249,113,000 after purchasing an additional 903,334 shares during the period. Dodge & Cox grew its position in shares of Cigna Group by 19.7% in the 4th quarter. Dodge & Cox now owns 11,138,614 shares of the health services provider's stock valued at $3,065,681,000 after purchasing an additional 1,833,389 shares during the period. Finally, Sanders Capital LLC grew its position in shares of Cigna Group by 0.5% in the 3rd quarter. Sanders Capital LLC now owns 7,828,168 shares of the health services provider's stock valued at $2,256,469,000 after purchasing an additional 35,150 shares during the period. Institutional investors own 86.99% of the company's stock.

Key Cigna Group News

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Q1 earnings and guidance — Cigna beat quarterly estimates (EPS $7.79) and raised 2026 adjusted EPS guidance to at least $30.35, improving earnings visibility and supporting valuation. Cigna posts Q1 beat as Evernorth powers topline growth
• Positive Sentiment: Evernorth driving revenue — the health‑services/pharmacy benefit business showed strong growth (single‑digit revenue gains), helping topline expansion even as pharmacy costs rose. This supports durable service‑fee revenue. Cigna Q1 Earnings Beat Estimates on Strong Evernorth Unit
• Positive Sentiment: Analyst sentiment and targets — Wall Street largely remains constructive (multiple buy ratings; median price target ~ $334), implying upside from current levels if execution continues. CIGNA ($CI) Releases Q1 2026 Earnings
• Neutral Sentiment: Bullish/valuation writeups — several investor notes and articles are re‑examining CI as a buying opportunity based on low forward P/E and the earnings beat; useful for longer‑term thesis but not a catalyst by itself. Is The Cigna Group (CI) A Good Stock To Buy Now?
• Neutral Sentiment: eviCore strategic review — management said it will pursue strategic alternatives for eviCore (radiology/utilization management), which could lead to asset sales or restructuring; outcome and timing remain uncertain. Cigna to exit ACA market, pursue strategic alternatives for eviCore unit
• Negative Sentiment: Exit from ACA individual exchange — Cigna will leave the Affordable Care Act individual market in 2027, affecting roughly 369,000 members across ~11 states; that reduces future premium revenue and could spook investors focused on top‑line growth. Cigna is becoming the second major insurer to exit from the ACA market
• Negative Sentiment: Pharmacy/PBM cost pressure — commentary and coverage note persistent pharmacy benefit cost volatility; higher drug costs remain a headwind that could compress margins if not offset by Evernorth pricing or cost management. Cigna’s earnings could show it has cleared away PBM surprises

About Cigna Group

Cigna Group NYSE: CI is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.